Evidence map›Paper›PMID 32348306›Full record

Trial reportPloS one2020

Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): A randomized controlled clinical trial.

Kristin V Carson-Chahhoud, Brian J Smith, Matthew J Peters, Malcolm P Brinn, Faisal Ameer, Kuljit Singh, Robert Fitridge, Simon A Koblar, Jim Jannes, Antony J Veale and 3 more

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Interventions for smoking cessation in hospitalised patients.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Kristin V Carson-ChahhoudAustralian Centre for Precision Health, School of Health Sciences, The University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0001-9966-9289
Brian J SmithSchool of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
Matthew J PetersThoracic Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Malcolm P BrinnAustralian Centre for Precision Health, School of Health Sciences, The University of South Australia, Adelaide, South Australia, Australia.
Faisal AmeerRespiratory Medicine, Ipswich Hospital, Ipswich, Queensland, Australia.
Kuljit SinghSchool of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
Robert FitridgeDivision of Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Simon A KoblarStroke Research Programme, University of Adelaide, Adelaide, South Australia, Australia.
Jim JannesStroke Research Programme, University of Adelaide, Adelaide, South Australia, Australia.
Antony J VealeRespiratory Medicine Department, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Sharon GoldsworthyPharmacy Department, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Khin HninDepartment of Respiratory and Sleep Medicine, Flinders Medical Centre, Adelaide, South Australia, Australia.
Adrian J EstermanSchool of Nursing and Midwifery, The University of South Australia, Adelaide, South Australia, Australia.
Queen Elizabeth Hospital · AUUniversity of South Australia · AUThe University of Adelaide · AUConcord Repatriation General Hospital · AUFlinders Medical Centre · AUGold Coast Hospital · AUIpswich Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVarenicline tartrate is superior for smoking cessation to other tobacco cessation therapies by 52 weeks, in the outpatient setting. We aimed to evaluate the long-term (104 week) efficacy following a standard course of inpatient-initiated varenicline tartrate plus Quitline-counselling compared to Quitline-counselling alone.

methodsAdult patients (n = 392, 20-75 years) admitted with a smoking-related illnesses to one of three hospitals, were randomised to receive either 12-weeks of varenicline tartrate (titrated from 0.5mg daily to 1mg twice-daily) plus Quitline-counselling, (n = 196) or Quitline-counselling alone, (n = 196), with continuous abstinence from smoking assessed at 104 weeks.

resultsA total of 1959 potential participants were screened for eligibility between August 2008 and December 2011. The proportion of participants who remained continuously abstinent (intention-to-treat) at 104 weeks were significantly greater in the varenicline tartrate plus counselling arm (29.2% n = 56) compared to counselling alone (18.8% n = 36; p = 0.02; odds ratio 1.78; 95%CI 1.10 to 2.86, p = 0.02). Twenty-two deaths occurred during the 104 week study (n = 10 for varenicline tartrate plus counselling and n = 12 for Quitline-counselling alone). All of these participants had known or developed underlying co-morbidities.

conclusionsThis is the first study to examine the efficacy and safety of varenicline tartrate over 104 weeks within any setting. Varenicline tartrate plus Quitline-counselling was found to be an effective opportunistic treatment when initiated for inpatient smokers who had been admitted with tobacco-related disease.

Indexed as

AdultAgedFemaleHumansInpatientsMaleMiddle AgedNicotianaNicotinic AgonistsOutpatientsSmokingSmoking CessationTobacco SmokingTreatment OutcomeVareniclineNicotinic AgonistsVarenicline

Identifiers

PMID32348306
PMCPMC7190140
OpenAlexW3018472192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.